| Literature DB >> 16485481 |
Marcia L Kalish1, Nathan D Wolfe, Clement B Ndongmo, Janet McNicholl, Kenneth E Robbins, Michael Aidoo, Peter N Fonjungo, George Alemnji, Clement Zeh, Cyrille F Djoko, Eitel Mpoudi-Ngole, Donald S Burke, Thomas M Folks.
Abstract
HIV-seronegative Cameroonians with exposure to nonhuman primates were tested for simian immunodeficiency virus (SIV) infection. Seroreactivity was correlated with exposure risk (p<0.001). One person had strong humoral and weak cellular immune reactivity to SIVcol peptides. Humans are exposed to and possibly infected with SIV, which has major public health implications.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16485481 PMCID: PMC3367631 DOI: 10.3201/eid1112.050394
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Simian immunodeficiency (SIV) multiple antigenic peptide–enzyme immunoassay (SMAP-EIA) seroreactivity trends to SIV immunodominant region (IDR) peptides in HIV-seronegative Cameroonian population groups with different levels of exposure (high exposure [HE], low exposure [LE], or general [G]) to nonhuman primates. OD, optical density. χ2 linear trend 48.166, p<0.001.
Figure 2Interferon-γ enzyme-linked immunospot reactivity stimulated with SIVcol peptides from the env and gag regions in peripheral blood lymphocytes (PBLs) from a person seropositive for both the SIVcol V3 and immunodominant region (IDR) peptides and a seronegative person from Africa (both men). To include both assays in a single graph, the number of spots per 106 PBLs for each pool of gag peptides was divided by the number of spots per 106 PBLs in the medium control. This value was expressed as the level of reactivity above background; i.e., the value 2 on the y-axis stands for 2× the number of spots in the negative (medium) control.